Optimization of reactive arthritis treatment using systemic enzyme therapy
Mazurov V.I., Lila A.M. Optimization of reactive arthritis treatment
using systemic enzyme therapy. Int. J. Immunotherapy 2001, Vol.
XVII, No. 2/3/4, pp. 125-128
- ISSN 0255-9625. 218 K/375 (19-05-3)
We studied 28 cases of the genitourinary variant of chlamydial
reactive arthritis (ReA). All patients wore divided into two groups.
Group 1 included 17 patients who received antibacterial therapy (Tarivid®,
Sumamed®), nonsteroid antiinflammatory drugs (NSAIDs) (diclofenac,
Movalis®) and Phlogenzym®. Group 2 included 11 patients
who received antibiotics and NSAIDs. We dynamically evaluated
general, biochemical and immunological blood parameters including
the patients' interferon profile.
The results showed that ReA patients included in group 1 who
received complex therapy with Phlogenzym® showed faster
relief of manifestations of joint lesion syndrome, a decrease in
laboratory evidence of disease activity and normalization of
interferon profile. In addition, the effect of antibacterial drugs
was improved and chlamydia elimination was more effective.